Skip to main content
Fig. 5 | BMC Complementary and Alternative Medicine

Fig. 5

From: Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis

Fig. 5

High-through-put study design. The basic study layout consisted of a primary first level tier 1 screening by which all CAMs were tested to reduce NO2- in LPS treated BV-2 and RAW 264.7 cells [maximum working concentrations were : 230μg/mL (plant based) and 92μg/ml (metabolites, drugs and polyphenolics)]. a, b Compounds displaying an IC50 below the 1st tier concentrations were further evaluated as per the template (c). All compounds were simultaneously evaluated for toxicity/anti-inflammatory effects and an iEI differential was established (LC50/IC50) to prevent false positives incurred by cytotoxic effects

Back to article page
\